News
Recent psoriasis pathophysiology insights carry treatment implications
“The primary problem in psoriasis is not so much the inflammatory activity, but the ability to turn off the activity.”
News
RA experts highlight key developments over the past year
Highlights include lymphoma risk reduction with biologics, low-dose corticosteroid risk, stratifying VTE risk, treat-to-target strategies and...
News
Rise of JAK inhibitors highlights axial spondyloarthritis year in review
Panelists at the 2021 Rheumatology Winter Clinical Symposium discussed the impact JAK inhibitors will have on the management of patients with...
News
Romosozumab may not increase cardiovascular risk after all
Could a cardioprotective effect of bisphosphonates in a pivotal clinical trial of romosozumab explain why the biologic was given a black-box...
News
Consider home subcutaneous immune globulin for refractory dermatomyositis
Patients prefer home subQ over IVIg, citing greater feeling of autonomy.
News
Molecular insights suggest novel therapies for hidradenitis suppurativa
Many key molecular pathways involved in HS pathogenesis can be targeted by commercially available agents having other indications.
News
Anybody for a nanobody? Novel psoriasis therapy impresses in phase 2b
Sonelokinab, which inhibits interleukin-17A/F, provided exceptionally rapid clinical improvement.
News
Neoadjuvant immunotherapy shows promise in stage III melanoma
There is both preclinical and clinical evidence that neoadjuvant therapy may offer a survival advantage over adjuvant therapy.
News
Delusional infestation surges during COVID-19 pandemic
Experts weigh in on management of this challenging disorder marked by tenacious false beliefs.
News
Adalimumab enhances primary wound closure after HS surgery
Primary wound closure following surgery for HS is controversial.
News
Hypochlorous acid is a valuable adjunctive treatment in AD
Stabilized topical hypochlorous acid has potent antimicrobial and antipruritic effects.
News
Topical brepocitinib for atopic dermatitis meets endpoints in phase 2b study
First-in-class inhibitor of tyrosine kinase 2 and Janus kinase 1 scores for mild-to-moderate AD.
News
Expert highlights advances in DRESS
Recent data demonstrate that DRESS symptoms often occur within just a week or two of drug exposures.
News
Oral JAK1 inhibitor shows promise for hidradenitis suppurativa
Favorable safety and efficacy shown in phase 2, proof-of-concept studies.
News
Guselkumab maintains psoriasis efficacy long after discontinuation
A potential flexible dosing indication for the IL-23 inhibitor is under study.